New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 19, 2012
13:40 EDTCI, BSX, MDT, AET, HUM, HS, CNC, AGP, WLP, CVH, UNH, MOH, HNT, WCG, STJBattles over ObamaCare still loom, The Hill says
Medical device companies are trying to use the debate over tax reform to get ObamaCare's tax on medical devices repealed, and some Democrats support that initiative, according to The Hill. Meanwhile, some insurers believe the government may slow the implementation of rules limiting the amount that older people can be charged for insurance, the publication added. Reference Link
News For CI;WCG;HNT;MOH;UNH;CVH;WLP;AGP;CNC;HS;HUM;AET;MDT;BSX;STJ From The Last 14 Days
Check below for free stories on CI;WCG;HNT;MOH;UNH;CVH;WLP;AGP;CNC;HS;HUM;AET;MDT;BSX;STJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 7, 2014
12:29 EDTUNH, WLP, AET, CIHealth insurers fall after two downgrades from Goldman
Shares of a number of health insurers are falling after Goldman Sachs downgraded its rating on one stock in the sector and removed another from its Conviction List. WHAT'S NEW: Goldman analyst Matthew Borsch downgraded his rating on Aetna (AET) to Neutral from Buy and removed UnitedHealth (UNH) from the firm's Conviction List, as he believes that other stocks in the healthcare sector are more attractive. Utilization of healthcare services by individuals who don't have the Affordable Care Act is likely to show signs of increasing by 2015, posing a "manageable" challenge to health insurers, Borsch wrote. However, the increase in the utilization of these services is likely to be "relatively gradual" compared with similar trends in the past, the analyst contended. Borsch based his forecast on healthcare spending trends during previous economic recoveries. He reduced his 2015 earnings estimate for Aetna to $7 from $7.10 and for United Health to $5.95 from $6. He reduced his 2015 EPS estimates for other companies in the sector, as his earnings outlook for WellPoint (WLP) declined to $9.20 from $9.35, while his estimate for Cigna (CI) for next year dropped to $7.90 from $8. The analyst kept Neutral ratings on both WellPoint and Cigna. Meanwhile, Borsch cut his price target on Aetna to $88 from $91 and on UnitedHealth to $91 from $96. PRICE ACTION: In early afternoon trading, Aetna fell 3% to $76, UnitedHealth slumped 2.5% to $79.50, WellPoint declined 2.5% to $108, and Cigna retreated 2.5% to $89.
10:00 EDTUNH, AETOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:31 EDTMDTMedtronic receives FDA approval for Attain Performa quadripolar lead
Subscribe for More Information
08:58 EDTMDTMedtronic receives request of additional info from FTC for Covidien acquisition
On August 6, 2014, in connection with the FTC review of the pending acquisition by Medtronic (MDT) of Covidien (COV), which will result in both Medtronic and Covidien becoming wholly owned subsidiaries of Medtronic, Medtronic received a request for additional information and documentary material from the FTC. Issuance of the second request extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 until 30 days after Medtronic and Covidien have substantially complied with the second request, unless the waiting period is extended voluntarily by the parties or terminated earlier by the FTC. Medtronic and Covidien intend to cooperate fully with the FTC and continue to expect the Transaction to be completed in the fourth calendar quarter of 2014 or early 2015.
08:26 EDTMDTMedtronic risk/reward attractive, says Morgan Stanley
Subscribe for More Information
08:16 EDTSTJSt. Jude Medical completes acquisition of NeuroTherm
Subscribe for More Information
06:42 EDTMDTObama to look to limit inversion deals, Politico says
Subscribe for More Information
05:41 EDTAETAetna downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded Aetna to Neutral citing less favorable sector trends. The firm lowered its price target for shares to $88 from $91.
05:40 EDTUNHUnitedHealth downgraded to Buy from Conviction Buy at Goldman
Goldman Sachs downgraded UnitedHealth to Buy saying it sees better opportunities elsewhere within healthcare given its expectations for a stronger utilization environment. The firm dropped its price target for shares to $91 from $96.
August 6, 2014
18:15 EDTBSXBoston Scientific discloses subpoenas in 10-Q filing
Subscribe for More Information
13:42 EDTMDTMedtronic says approval for Covidien deal 'progressing'
Subscribe for More Information
13:39 EDTMDTMedtronic CEO says Covidien deal should close end of year, early next
Subscribe for More Information
13:38 EDTMDTMedtronic CEO says 'progressing' in Covidien deal approval process
Subscribe for More Information
12:59 EDTMDTCovidien drops as Treasury explores ways to stymie inversions
Shares of medical device and drug maker Covidien (COV) are falling after multiple media outlets reported that the Treasury Department is looking into ways of curtailing tax inversion deals. Covidien has agreed to be acquired by Medtronic (MDT) in a tax inversion deal. BACKGROUND: Tax inversions refer to an acquisition of one company, usually officially based in a country in Europe or elsewhere, by a U.S. company, following which the acquiring company becomes domiciled in the same country as the company that it bought. The switch has the potential to significantly lower the acquiring company's tax rate. WHAT'S NEW: The Treasury Department is looking at options that would enable the Obama administration to curtail inversion deals without authorization from Congress, multiple media outlets reported last night and today. ANALYST REACTION: In a note to investors today, Wells Fargo analyst Larry Biegelsen wrote that he believes that Medtronic would buy Covidien even if the transaction cannot be done as an inversion. At a conference in June, Medtronic CFO Gary Ellis said that his company would "do the deal whether it's an inversion or not inversion," Biegelsen stated. If no inversion is possible, Medtronic would respond by using less of its stock and more debt to fund the transaction, the analyst believes. Such a change would actually cause Medtronic's cash earnings per share to be higher in the first and second year after the deal than under the current structure, the analyst indicated. He kept an Outperform rating on Medtronic. PRICE ACTION: In early afternoon trading, Covidien dropped 2% to $84.50 and Medtronic fell 1% to $61.50. Meanwhile, drug maker Shire (SHPG), which has agreed to merge with its peer AbbVie (ABBV) in a tax inversion deal, is falling 4% to $236.
12:20 EDTMDTMedtronic remains committed to Covidien deal, says Wells Fargo
Following recent conversations with the company, Wells Fargo believes Medtronic (MDT) remains committed to the acquisition Covidien (COV), even if the deal can't be structured as an inversion. The firm notes that at its conference in June, Medtronic CFO Gary Ellis stated that "from Medtronic's perspective, we would do the deal whether it's an inversion or not inversion." Wells adds, however, that Medtronic would likely try to renegotiate the terms of the deal if an inversion is not possible.
11:14 EDTHNTHealth Net expects DCP to move lower in 2H14
Subscribe for More Information
08:39 EDTHNTHealth Net backs view for FY14 GAAP EPS at least $3.00
Subscribe for More Information
08:36 EDTHNTHealth Net reports Q2 EPS 42c, consensus 56c
Subscribe for More Information
06:41 EDTMDTObama administration may restrict inversion tax benefits, NY Times says
Subscribe for More Information
06:21 EDTMDT, UNHPiper Jaffray to hold a summit
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use